Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity (2020 - 2025)

Caribou Biosciences has reported Common Equity over the past 6 years, most recently at $122.2 million for Q4 2025.

  • Quarterly Common Equity fell 51.7% to $122.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.2 million through Dec 2025, down 51.7% year-over-year, with the annual reading at $122.2 million for FY2025, 51.7% down from the prior year.
  • Common Equity was $122.2 million for Q4 2025 at Caribou Biosciences, down from $141.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $404.4 million in Q3 2021 and troughed at -$47.7 million in Q2 2021.
  • The 5-year median for Common Equity is $291.0 million (2022), against an average of $260.2 million.
  • The largest YoY upside for Common Equity was 3707.18% in 2021 against a maximum downside of 1599.48% in 2021.
  • A 5-year view of Common Equity shows it stood at $387.8 million in 2021, then fell by 22.42% to $300.9 million in 2022, then grew by 22.44% to $368.4 million in 2023, then tumbled by 31.34% to $253.0 million in 2024, then crashed by 51.7% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Common Equity are $122.2 million (Q4 2025), $141.8 million (Q3 2025), and $166.1 million (Q2 2025).